Viatris Launches $1.65 Billion All‑Cash Tender Offer for Pacira BioSciences

Viatris Inc. (Nasdaq: VTRS) has formally launched an all-cash tender offer to acquire Pacira BioSciences for approximately $1.65 billion, offering $36.50 per share. The offer includes a $62 million break fee and is structured as a no-vote second‑step merger, placing Viatris ahead in expanding its footprint in the non-opioid pain treatment space. The development comes by way of Viatris’s press release this week.

The tender offer announcement was first reported on October 8, 2026. It is a completed strategic decision as of that date and is not merely a proposal or intent. Under the terms, Pacira shareholders will receive $36.50 in cash for each Pacira share, and if the deal fails to close under specified conditions, a $62 million break fee will apply. Viatris is using a no-vote second-step merger structure, which would streamline the acquisition following the successful tender of shares.

This move is significant for Viatris’s strategic positioning. By targeting Pacira, a company with a portfolio centered on non-opioid pain management therapies, Viatris is reinforcing its focus on innovative pain solutions amid the industry’s shift away from opioid reliance. The acquisition aligns with recent company initiatives such as its FDA acceptance of a new drug application for fast-acting meloxicam earlier this year, although no direct causal link between those and the current offer has been established.

The tender offer is a material development in the pharmaceutical and biotech sector, offering clear implications for Viatris’s product portfolio and long-term strategy. The $1.65 billion valuation underscores the value Viatris places on consolidating Pacira’s non-opioid assets, while the deal structure—with its break fee and merger plan—demonstrates Viatris’s intent to bring the deal to completion efficiently.

Investors in VTRS should monitor updates on tender offer progress, regulatory filings regarding the acquisition, and potential impacts on Viatris’s financial outlook. While the tender offer is set, the deal remains subject to regulatory and shareholder approval before finalization. That said, this marks a notable expansion in Viatris’s portfolio strategy in the current week.

Stock Note: The verified live trading price for VTRS as of October 9, 2026, was $17.64, representing a 1.61% change. This figure is independently verified and presented without conjecture on causation linking the tender offer announcement with the share price movement.